Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Dermatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
INTERVENTIONAL
Inicio: 5 de abr de 2023
ID: NCT05795153
Completado
Fase 3
ClinicalTrials.gov
The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 1 de sept de 2012
ID: NCT01617434
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-Site, Randomized, Mixed-Blind, Parallel-Group Treatment Withdrawal And Re-Treatment Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
INTERVENTIONAL
Inicio: 1 de sept de 2010
ID: NCT01186744
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)
INTERVENTIONAL
Inicio: 11 de mar de 2019
ID: NCT03823300
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 18 de oct de 2022
ID: NCT05559359
Completado
Fase 3
ClinicalTrials.gov
A Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
INTERVENTIONAL
Inicio: 31 de ene de 2016
ID: NCT02501161
Completado
Fase 3
ClinicalTrials.gov
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
INTERVENTIONAL
Inicio: 1 de nov de 2013
ID: NCT01836523
Completado
Fase 3
ClinicalTrials.gov
A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00566657
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)
INTERVENTIONAL
Inicio: 11 de jul de 2024
ID: NCT06445023
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment
INTERVENTIONAL
Inicio: 29 de feb de 2024
ID: NCT06241118
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)
INTERVENTIONAL
Inicio: 13 de sept de 2023
ID: NCT05878717
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
INTERVENTIONAL
Inicio: 4 de sept de 2024
ID: NCT06550076
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV Doses of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 2 de sept de 2021
ID: NCT04990440
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Parallel-group, Open-labelled, Multinational Trial Comparing the Efficacy and Safety of Insulin Detemir (Levemir®) Versus Human Insulin (NPH Insulin), Used in Combination With Insulin Aspart as Bolus Insulin, in the Treatment of Pregnant Women With Type 1 Diabetes
INTERVENTIONAL
Inicio: 1 de may de 2007
ID: NCT00474045
Completado
Fase 3
ClinicalTrials.gov
A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
INTERVENTIONAL
Inicio: 28 de jul de 2012
ID: NCT01646177
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes
INTERVENTIONAL
Inicio: 1 de ene de 2007
ID: NCT00366249
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 13 de ago de 2018
ID: NCT03569293
Completado
Fase 3
ClinicalTrials.gov
Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
INTERVENTIONAL
Inicio: 4 de jun de 2018
ID: NCT03548935
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of IV to Oral 6-Day TR-701 Free Acid and IV to Oral 10-Day Linezolid for the Treatment of ABSSSI
INTERVENTIONAL
Inicio: 15 de sept de 2011
ID: NCT01421511
Completado
ClinicalTrials.gov
Multi-Country Prospective ObserVAtionaL, Cohort Study of Patients With Moderate to Severe Chronic PlaqUE Psoriasis (VALUE)
OBSERVATIONAL
Inicio: 1 de jul de 2019
ID: NCT03982394
Anterior
1
...
7
8
9
...
434
Siguiente
Filtros